To evaluate the relationship between aspirin ingestion and postoperative bleeding complications, and to test the hypothesis that there is a subset of patients who are aspirin hyperresponders with a proclivity toward platelet dysfunction.
Objective
To evaluate the relationship between aspirin ingestion and postoperative bleeding complications, and to test the hypothesis that there is a subset of patients who are aspirin hyperresponders with a proclivity toward platelet dysfunction.
Summary Background Data
Despite numerous retrospective and prospective analyses, it is still controversial as to whether aspirin ingestion before coronary artery bypass grafting (CABG) is associated with significant postoperative bleeding.
Methods
Between January 1995 and December 1999, the records of 2,606 consecutive patients undergoing CABG were reviewed to identify patients with a history of aspirin ingestion up until the time of surgery. Aspirin ingestion was correlated with postoperative blood transfusion using multivariate analysis. In a subset of preoperative aspirin users (n ϭ 40), bleeding times were measured before and after aspirin use. Flow cytometry was performed in another cohort of patients with known heart disease (n ϭ 30) to determine the effect of aspirin on platelet surface receptors.
Results
During the 5-year study period, 63% of the CABG patients were identified as aspirin users. Among these, 23.1% required blood transfusions compared with 19% for the nonusers. Non-red blood cell transfusions were more common in aspirin users, as was reexploration for bleeding. Stratification of these results according to the frequency of aspirin use showed that aspirin is an independent multivariate predictor of postoperative blood transfusion only in high-risk patients. In the prospective studies, aspirin treatment resulted in a significant increase in the template bleeding time, an increase in platelet PAR-1 thrombin receptor activity, and a decrease in the binding of platelets to monocytes.
Conclusions
The findings support the hypothesis that aspirin is associated with a greater likelihood of postoperative bleeding. A platelet function testing algorithm that combines preoperative risk factor assessment, template bleeding times, and flow cytometry may allow the identification of aspirin hyperresponders who are at increased risk for bleeding.
Aspirin reduces the risk of myocardial infarction 1,2 and has been shown to improve graft patency rates after coronary artery bypass grafting (CABG). 3, 4 Paradoxically, the very mechanisms that confer protection against myocardial infarction and graft closure may also contribute to increased bleeding complications after cardiac surgery. This conclusion is based on the findings of several randomized clinical trials in which the incidence of bleeding complications after CABG is greater in patients who take aspirin before surgery. [5] [6] [7] [8] Unfortunately, in these studies, either the number of patients enrolled was small or the authors failed to clarify whether the risk of bleeding associated with aspirin use is significant enough to warrant either cessation of aspirin or administration of hemostatic agents to diminish bleeding. These trials did result, however, in a number of clinical trials (both prospective and retrospective) that tested the efficacy of various antifibrinolytic agents (mainly aprotinin) in limiting aspirin-induced postoperative bleeding. 9 -12 A number of other studies indicate that aspirin ingestion is not associated with postoperative bleeding. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] This may be due to other confounding factors that contribute to the problem of postoperative bleeding that are independent of platelet-related abnormalities. Some examples include problems with surgical hemostasis, the direct and indirect effects of cardiopulmonary bypass, and drug-induced coagulopathies, especially those related to heparin/protamine administration. In addition, it is often difficult to identify why some patients receive aspirin before surgery and others do not. This uncertainty may introduce a patient selection bias and certainly could explain why there are so many conflicting reports regarding the association between aspirin ingestion and postoperative bleeding.
For these reasons, we reviewed our own experience with postoperative bleeding after CABG and tested the hypothesis that there is a subpopulation of aspirin hyperresponsive patients with a proclivity toward platelet dysfunction. This may partly explain why some patients who take aspirin before CABG experience significant postoperative bleeding but others do not.
METHODS

Retrospective Analysis
Between January 1995 and December 1999, the Society of Thoracic Surgeons' National Cardiac Database at St. Mary's Regional Medical Center was used to identify patients undergoing CABG alone or CABG in conjunction with another procedure. From this group, a cohort of patients with a history of aspirin ingestion within 12 hours of surgery was identified. Postoperative banked red blood cell use and transfusion of non-red blood cell products (freshfrozen plasma, platelets, and cryoprecipitate) were recorded for both aspirin users and nonusers. Preoperative aspirin ingestion was then correlated with the rates of postoperative transfusion and the frequency of operative reexploration for bleeding.
In addition, more than 80 preoperative and intraoperative variables obtained from the database were used to identify multivariate correlates of postoperative blood transfusion, and to match aspirin users and nonusers for commonly identified risk factors of postoperative blood transfusion. Variables such as gender, age, bypass time, renal function, prior cardiac operation, preoperative medications other than aspirin, and preoperative congestive heart failure were included in this list of additional variables.
Prospective Studies
Bleeding Times
In a separate group of patients (n ϭ 40), preoperative template bleeding times before and after a single oral dose of aspirin (325 mg) were measured using the Simplate II device (Curtin Matheson, Broadview Heights, OH). Results of bleeding times were recorded as the nearest half-minute after which no additional blood could be blotted from the forearm incision.
Platelet Surface Receptor Studies: Flow Cytometry
In another group of patients with known coronary artery disease (n ϭ 30), platelet surface receptor activity was measured before and after aspirin ingestion (325 mg). The following markers of platelet activation were studied: fibrinogen receptor (glycoprotein IIb/IIIa), human monocyte binding receptor, PAR-1 thrombin receptor, and von Willebrand receptor (glycoprotein Ib/IX). These receptors were selected because they are representative of the sites involved in platelet activation that are associated with platelet dysfunction and bleeding after cardiac surgery. 27 The monoclonal antibodies used to study specific platelet surface receptors included PAC-1-FITC (for the platelet fibrinogen receptor), CD 14-FITC (for monocytes), CD 45-PerCP (for human leukocytes of any type), WEDE-15 (for total PAR-1 platelet thrombin receptor), SPAN-12 (for noncleaved PAR-1 thrombin receptor), and CD 42b-PE (for platelet von Willebrand receptor).
Whole blood was used in the measurement of the platelet fibrinogen receptor and the von Willebrand receptor and for platelet-monocyte binding studies. For these studies, whole blood was diluted 1:10 in a modified Tyrode's buffer (0.35% bovine serum albumin and 5.5 mmol/L glucose, pH 7.4). Forty-five microliter aliquots were then incubated at room temperature with a saturating concentration of the appropriate antibodies before analysis by flow cytometry using a FACScan Flow Cytometer (Becton-Dickinson, Mountain View, CA), using Becton-Dickinson's Cell Quest software for analysis.
Platelet-rich plasma (PRP) was used to measure the platelet PAR-1 receptor. PRP was diluted 1:10 in modified Tyrode's buffer and the samples were incubated for 15 minutes with WEDE-15 (for combined activated or nonactivated receptor) or with SPAN-12 (for nonactivated receptor only). After this a secondary antibody, GAM-PE, was added to all samples. After fixation with 1% paraformaldehyde, PRP samples were run on a flow cytometer within 24 hours.
Statistical Analysis
For the retrospective studies, multivariate logistic analysis was used to determine risk factors for any postoperative blood transfusion. SPSS Statistical Software for Windows (SPSS Inc., Chicago, IL), version 10.1.4, was used to construct the multivariate models. Propensity scores, corrected for all other measured preoperative and intraoperative variables, were used to quantify each patient's probability of receiving preoperative aspirin. 28, 29 To explore the causative Aspirin and Bleeding After CABG effect of aspirin on postoperative blood transfusion, patients were matched according to their propensity scores (i.e., the probability of receiving preoperative aspirin). Patients were stratified into quintiles based on their propensity scores and evaluated across all quintiles according to the effect of aspirin on postoperative blood transfusion.
For the prospective studies, data are reported as means Ϯ standard deviation and the 95% confidence intervals. Differences among groups were analyzed using one-way analysis of variance and, if appropriate, were followed by t tests with Bonferroni correction. A probability of 0.05 or less was considered significant.
RESULTS
Retrospective Analyses
During the time interval studied, 2,793 patients underwent cardiac surgery. Of these, 2,606 patients underwent CABG alone or in combination with other cardiac procedures. In the CABG group, 63% (1,900/2,606) ingested aspirin within 12 hours of surgery.
Effect of Aspirin on Postoperative Bleeding
Among the aspirin users, 23.1% (437/1,900) received a postoperative blood transfusion versus 19.0% (134/706) of the nonusers (P ϭ .027). The number of patients receiving fresh-frozen plasma, platelet transfusions, and/or cryoprecipitate was more than twofold greater in the aspirin group: 4.5% (88/1,900) aspirin users versus 2.1% (15/706) for nonusers (P ϭ .009). Reoperation for excessive postoperative bleeding was also more common among the aspirin group: 3.7% (71/1,900) versus 2.0% (14/706) (P ϭ .01).
Stratification Based on Likelihood of Receiving Aspirin
Patients were divided into five equal quintiles based on their propensity scores (logistic probability of receiving aspirin before surgery). Scores were computed by entering all preoperative and perioperative variables into a stepwise logistic regression analysis to determine the probability (or propensity) of receiving aspirin. Bootstrapping was used to obtain the best estimate of the propensity scores. 30 Within each quintile, postoperative blood product transfusion in aspirin users was compared with that in nonusers. Table 1 shows that the risk of receiving a postoperative blood transfusion was greatest for aspirin users in quintile 1. This indicates that the patients least likely to receive aspirin before surgery were most likely to receive a blood transfusion after surgery if they ingested aspirin. Propensity score matching ensured that for selected covariates known to be associated with increased postoperative bleeding (advanced age, female gender, renal insufficiency, redo procedure, and chronic lung disease), the frequency of these variables was similar for both aspirin users and nonusers across all quintiles.
Major Risk Factors for Bleeding and Selection Bias
Preoperative ingestion of aspirin was an independent predictor of postoperative blood transfusion in the nonpropensity-matched groups ( Table 2 ). Other important independent predictors of postoperative blood transfusion in the population include the surgeon performing the operation, female gender, advanced age, renal dysfunction, and chronic obstructive lung disease.
To minimize the adverse effects of selection bias and to provide greater confidence of any causal effect of aspirin on postoperative bleeding, propensity score matching was used to compare equivalent groups of patients receiving postoperative nonautologous blood with those who did not. Variables that were independent predictors of postoperative blood transfusion (from Table 2 ) were entered into a separate logistic regression within each propensity-matched quintile. Table 3 shows the result of this analysis. Quintile 1 is the only quintile in which aspirin is an independent predictor of postoperative blood transfusion. As shown in Table 2 , quintile 1 contains the patients with the least chance of receiving preoperative aspirin and the highest chance of receiving a postoperative blood transfusion.
Prospective Studies
Effect of Aspirin on Bleeding Time and Platelet Surface Receptors
Aspirin treatment resulted in a significant increase in template bleeding times (Fig. 1) . The mean bleeding time increased from 6.0 Ϯ 1.3 minutes before aspirin to 8.9 Ϯ 3.6 minutes after aspirin (P Ͻ .001). Four of 40 patients (10%) had template bleeding times greater than 15 minutes after aspirin ingestion.
The flow cytometric results for three platelet surface receptors are shown in Figure 2 . Aspirin caused a 12% increase in both total thrombin receptor and uncleaved thrombin receptor activity (P ϭ .01). Aspirin also induced a 25% decrease in the binding of platelets to monocytes (P ϭ .009), but it had no effect on fibrinogen receptor or von Willebrand receptor.
DISCUSSION
The results of this study support the hypothesis that aspirin causes increased postoperative bleeding. All parameters of postoperative bleeding, including blood transfusion, transfusion of platelets or plasma, and reexploration for postoperative hemorrhage, were more common in the aspirin users. These findings are consistent with those reported by other researchers. 5, 7, 8, [21] [22] [23] [24] [25] [26] 31, 32 Resolution of the controversy, however, requires a large prospective, randomized controlled study. Until such a study is performed, we will have to rely on retrospective studies such as ours that use bias-reduction techniques such as propensity scoring. This methodology provides reliable information about cause and effect from nonrandomized comparisons. 29, 33 Although this is not a substitute for randomized clinical trials, it is a less costly and more versatile alternative. This method of comparison (balancing) allows more exact matching of patients Aspirin and Bleeding After CABG over the entire dataset and demonstrates that when our patients were matched as closely as possible, there was a significant difference in the rate of postoperative blood transfusion in certain high-risk strata.
When an aspirin-related difference in blood transfusion did not occur across all quintiles, other (unmeasured) patient factors (e.g., aspirin hypersensitivity) may have influenced the rate of postoperative blood transfusion. Alternatively, this finding may indicate that selection bias actually existed within the dataset (i.e., for unknown reasons certain patients were not given aspirin before surgery).
The fact that the propensity-scored quintiles are asymmetric shows that there is not a consistent association of aspirin with postoperative blood transfusion across all quin-tiles. At the same time, in the strata of patients least likely to receive preoperative aspirin, there are patients who are more likely to receive postoperative transfusion (i.e., quintile 1 patients have the longest cardiopulmonary bypass time, the greatest number of women, and the largest number of patients with preoperative renal dysfunction). This implies that some patients may have been recognized as high risk before surgery and were not administered aspirin. The corollary is that if this high-risk cohort received aspirin, there was an increased likelihood of receiving a postoperative blood transfusion.
With respect to the bleeding time study, at least 10% of our patients who received aspirin had bleeding times greater than 15 minutes. There is no simple explanation for why these patients had such prolonged bleeding times. It may be explained by the differences in aspirin absorption, 34 drug interactions (especially with heparin), 35 local conditions such as skin temperature, 36 or gene polymorphism. 37 In light of the platelet receptor findings in this study, another explanation may be that some patients are more sensitive to aspirin as a consequence of its effect on the platelet surface receptors. Unfortunately, we did not measure receptor activity in patients with bleeding times greater than 15 minutes.
In general, bleeding time is not a good predictor of postoperative bleeding due to its lack of specificity and high degree of sensitivity. 38, 39 Perhaps if bleeding time is combined with other risk-stratification techniques, the combination may better define the risk of postoperative bleeding. This could be particularly true for patients with advanced age or renal dysfunction, or in whom a prolonged operation is expected. In these patients, using hemostatic drugs (e.g., antifibrinolytics) and withholding aspirin before surgery may be useful adjuncts in preventing postoperative bleeding complications.
In summary, our understanding of the mechanism underlying the effect of aspirin on platelet function (inhibition of cyclooxygenase) has changed little since the original observations of Smith and Willis. 40 An interesting finding in this study was the effect aspirin had on specific platelet surface receptors. This suggests that other enzyme systems besides platelet cyclooxygenase are altered by aspirin. This in turn may explain why some patients are more inclined to experience postoperative bleeding after aspirin ingestion. If true, then a preoperative screening algorithm that uses risk factor analysis, bleeding times, and flow cytometry may be more useful in identifying patients at high risk for postoperative bleeding after CABG.
Discussion
DR. GORDON F. MURRAY (Morgantown, WV): I thank the authors for the opportunity to review the manuscript before the meeting and would like to comment on the retrospective analysis component of their study. In doing so, I would like to congratulate Dr. Mentzer on an excellent presentation and Dr. Ferraris on this, his most recent and sophisticated contribution to this subject. The authors' work suggests an association between preoperative aspirin ingestion and postoperative blood transfusion which was evaluated by multivariate analysis and propensity scoring, a statistical technique aimed at drawing causal inference from unrandomized comparison data. It is my understanding that a limitation which characterizes the propensity scoring methodology is that it cannot take into account unmeasured factors that should not and cannot be ignored. This understanding, or potentially lack of it, is the basis of my question for the authors. Intuitively it seems reasonable to assume that certain variables which have potential coagulation effects in the preoperative and operative period would be important factors to be measured. For example, complementary and alternative medicines are now very frequently consumed by our patients before surgery. Also, the number of surgeons using heparin up until the time of surgery and antifibrinolytics such as aprotinin in the perioperative period has markedly increased. Victor, what do you think is the statistical impact of the exclusion of these important variables, which are not available in the STS Society of Thoracic Surgeons database, which the authors utilized, on the validity of your current analysis? Further, the authors have also selected a cohort of patients with a history of aspirin ingestion within 12 hours of operation to be identified as aspirin users. Aspirin's action on platelets is irreversible, and it can have a lasting effect for many days. I think choosing this short time period may potentially overestimate the benefits of aspirin in a study of operative survival or graft patency, but it seems sure that it will underestimate the hemorrhagic morbidity of aspirin consumption; that is, there may be more postoperative blood transfusion in patients who have taken aspirin more than 24 hours before operation than those who have taken none at all, but they would all be included in the non-aspirin users' group. Dr. Ferraris, would you also comment on this concern? DR. HARRY A. WELLONS (Charlottesville, VA): I wish to thank Dr. Ferraris and Dr. Mentzer for the opportunity to review their manuscript and also to comment on their presentation. I think it is an excellent analysis of a large group of patients. The clinical experience of many of us in cardiac surgery is that aspirin does increase the problems with bleeding. From a management perspective, however, aspirin therapy is very problematic for several reasons. Some of the reasons have already been stated in the paper, such as the beneficial effects of aspirin in terms of reducing myocardial infarction and in long-term graft and early graft patency.
Another problem is that, unfortunately, a lot of the patients that we see are considered urgent, and most of these patients have already been started on aspirin therapy. So we really don't have much of a choice. The question then comes up: Does, in fact, the avoidance of aspirin therapy outweigh the benefits to be obtained by early operation on these patients, and the potential benefits, of course, of the aspirin therapy itself? In the paper that is presented here, we see that there is only a 4% increased risk in the rate of transfusion, a 2.5% increase in the use of blood products, and 1.7% increase in the rate of reexploration. Although these are significant, certainly one has to ask the question: Are these risks outweighed by the benefits of early operation? I have three questions to ask. One, was the quantity of transfused blood products increased in the patients that had aspirin therapy versus those that did not? Another question is, in the subgroup of patients which were studied with bleeding times and platelet function, has there been any clinical correlation observed with postop bleeding? Lastly, how has this study affected your postop management of patients?
DR. WALTER H. MERRILL (Nashville, TN): The authors are to be commended for bringing to our attention an important topic of wide concern. Perioperative bleeding can be an important source of morbidity. It may be linked directly or indirectly to the risk of death, it markedly increases the cost of care, and transfusion is associated with the risk of transmission of viral and other illnesses. This paper links the use of preoperative aspirin with the risk of postoperative bleeding. Patients who took aspirin within 12 hours of operation had an increased risk of requiring transfusion of blood products and reexploration for bleeding. Unlike Dr. Murray, I am not an expert in statistical methods, but I think the results in this study are quite valid, and I think they have been analyzed and controlled with appropriate statistical methodology. The additional studies regarding the effects of a single dose of aspirin on bleeding time and platelet surface receptors were very informative. On the whole, aspirin caused a statistically significant increase in bleeding time. Although many patients seemingly demonstrated no effect from aspirin, some had a quite remarkable prolongation of bleeding time. Likewise, the changes in the platelet surface receptor activity wrought by a single dose of aspirin reached statistical significance. As the previous discussant mentioned, I would question whether these effects of aspirin are truly of any clinical significance. I think the answer to that is unknown at this time. I have several questions for the authors. Did you analyze and control the use of additional preoperative medications? Some patients may have been taking other drugs, which might impact platelet function and the transfusion and reexploration rates. Do you have knowledge regarding aspirin ingestion greater than 12 hours preoperatively? This is obviously of some potential concern, as mentioned previously, due to the prolonged effects of aspirin on platelet function. Also, were the indications for transfusion and reexploration for bleeding consistently applied during the duration of the study among all the surgeons whose participated in the care of these patients? Were antifibrinolytic agents used during the study? Might they be of benefit in preventing bleeding, particularly in patients on aspirin preoperatively? Finally, what are your current recommendations regarding cessation of preoperative aspirin in patients who will undergo an elective procedure? Should those patients have operation delayed sufficiently until the effects of aspirin have been eliminated?
Congratulations on an interesting and informative study. Perhaps this work will stimulate additional investigation into what seem to be important differences in the response of individual patients to preoperative aspirin therapy.
DR. VICTOR A. FERRARIS (Lexington, KY): I appreciate the opportunity to present our work here. I would be remiss, and would run the risk of having to walk back to Lexington, if I didn't acknowledge my coworkers, one of whom is my wife, the other is Dr. Paulette Wehner. They played an important part in the prospective experiments that we presented here. I appreciate also the comments of the discussants, and I hope I can answer some of them. The manuscript contains some statistical data that may not be familiar to most surgeons. The propensity scoring that Dr. Murray mentioned is a way of dealing with retrospective data. The trouble with many studies that have been reported on the relationship between aspirin and bleeding is that they are retrospective and contain some element of selection bias. The propensity scoring is intended to reduce that bias. To give you an idea of how selection bias may impact on our results, in our study group only about two thirds of the patients received aspirin. This is a group where nearly 100% should receive aspirin based on multiple randomized clinical studies suggesting benefit from preoperative aspirin. So this suggests that for some reason clinicians withheld aspirin. That means that some unrecognized selection factors were used to decide who should get preoperative aspirin. Now, you can speculate about the reasons for withholding aspirin, but the fact is that our retrospective study, like many others, contains some element of selection bias. The propensity scoring mentioned by Dr. Murray and discussed in the manuscript allows you to adjust for this selection bias as much as possible.
There will undoubtedly be unmeasured variables that contribute to the outcome of bleeding that weren't included in the database; for example, some drug effects. One of the things that was measured in the database was preoperative heparin use. This is one of the variables measured in the STS data set. Preoperative heparin did not seem to predict postoperative bleeding. The propensity scoring can adjust for measured variables, such as preoperative heparin use, but not for unmeasured variables. Unfortunately, the unmeasured variables may be the subtle things on which clinicians base their decisions about preoperative aspirin. In the high-risk subset if, for some reason, the patients do get aspirin, they bleed excessively. And we are not talking about just a few blood transfusions; we are talking about many units of blood. Incidentally, our data supports the contention that if you receive 10 units or more of nonautologous blood products, your risk of dying from the operation is 10-to 15-fold greater. You can speculate about what that means, but certainly the amount of blood transfused is an important predictor of outcome.
There were two questions about how do we manage patients on preoperative aspirin. Because of time constraints it was not possible to go into the risk stratification of patients, but to summarize, we feel that there are certain high-risk patients that can be identified based on their preoperative risk factors. In those patients with a high-risk profile based on preoperative screening, a bleeding time will be helpful. If the bleeding time is excessively prolonged, it may be that flow cytometry measurements will be valuable in further segregating which patients are at a particularly high risk. So a stepwise risk analysis based on risk factors, on bleeding time, and on flow cytometry is a way that we believe will be helpful in sorting out which of these patients will have excessive postoperative bleeding.
There was a question about whether the decision to transfuse or to reoperate for bleeding was applied uniformly across the entire group. The answer is, we don't know, and I am sure there are surgeon differences. One of the ways we tried to account for that was to see if postoperative transfusions depended on which surgeon did the operation. The surgeon performing the operation did not turn out to be a significant predictor of postoperative transfusions. So we presumed that because the surgeonspecific rate of reoperation and rate of blood transfusion was not a significant factor, that the criteria for reoperation and the criteria for blood transfusion were applied relatively uniformly across the group.
There was a question about how to manage a high-risk patient once he/she is identified. Well, certainly the obvious thing is you don't give them aspirin. That is not always possible, especially in certain patients who need urgent operation. It may not be possible to wait 3 or 4 days until the aspirin effect goes away. So, in those patients, certain hemostatic drugs (for example, antifibrinolytics like aprotinin) may be helpful. Again, this is a matter of risk stratification and risk analysis.
I think I have covered most of the questions that were asked. I appreciate the opportunity to present our findings, and I thank the Association.
